<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00799890</url>
  </required_header>
  <id_info>
    <org_study_id>SUPREMES-01</org_study_id>
    <nct_id>NCT00799890</nct_id>
  </id_info>
  <brief_title>Sunphenon in Progressive Forms of Multiple Sclerosis</brief_title>
  <acronym>SUPREMES</acronym>
  <official_title>Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TAIYO EUROPE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that an oral Sunphenon EGCg (Epigallocatechin-Gallat, EGCG)
      treatment is - due to its antiinflamatoric and neuroprotective potence - significantly more
      effective than an oral placebo treatment regarding following parameters: increase in brain
      atrophy, number of new T2-lesions in the cerebral magnetic resonance tomography, reduction of
      the NAA/Cr-ratio in MR-spectroscopy, progression of disability such as cognitive disorders in
      patients with MS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypotheses of our study are:

      Sunphenon EGCg has an antiinflammatoric effect due to its impact on the T-cell-proliferation
      and the inhibition of the activity of NF-Kb.

      Sunphenon EGCg has a neuroprotective effect due to its antioxidative potence as a radical
      scavenger.

      A 30 month treatment with Sunphenon EGCg is safe and well-tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>brain atrophy</measure>
    <time_frame>36 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>new T2 lesions</measure>
    <time_frame>36 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reduction of the NAA/Cr-ratio in MR-spectroscopy</measure>
    <time_frame>36 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression of disability such as cognitive disorders</measure>
    <time_frame>36 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of AEs</measure>
    <time_frame>36 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Sunphenon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunphenon EGCG</intervention_name>
    <description>200-800mg (1-4 capsules)</description>
    <arm_group_label>Sunphenon</arm_group_label>
    <other_name>Epigallo Catechin Gallate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1-4 capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary or secondary chronic progressive multiple sclerosis (ms)

          -  EDSS 3-8

          -  Age 18-65

        Exclusion Criteria:

          -  Relapsing-remitting ms

          -  Immunodulatoric or immunosuppressive therapy

          -  pretreatment with Mitoxantron, Natalizumab, Rituximab, Azathioprin &lt;2 month before
             screening

          -  pretreatment with Glairameracetat or beta-Interferons &lt;4 weeks before screening

          -  signs of hepatic dysfunction

          -  active ulcus ventriculi or duodeni

          -  neoplasias if not cured &gt;1 year before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedemann Paul, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University (NeuroCure Clinical Research Center)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin (NeuroCure Clinical Research Center)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.charite.de/</url>
  </link>
  <link>
    <url>http://www.ncrc.de</url>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2008</study_first_submitted>
  <study_first_submitted_qc>November 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <name_title>Dr. Friedemann Paul</name_title>
    <organization>Charite University Berlin</organization>
  </responsible_party>
  <keyword>primary or secondary chronic-progressive</keyword>
  <keyword>sunphenon egcg</keyword>
  <keyword>brain atrophy</keyword>
  <keyword>T2 lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

